irAE Management for EC

CE / CME

Immune-Related Adverse Event Management and Supportive Care for Advanced Endometrial Cancer

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 18, 2023

Expiration: September 17, 2024

Activity

Progress
1 2
Course Completed

Introduction

In this module, Lauren Prescott, MD, MPH, provides a focused overview of multidisciplinary strategies for identifying and managing immune-related adverse events (irAEs) associated with immunotherapy-based regimens in patients with advanced endometrial cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

Poll

If you are a healthcare professional (HCP) providing patient care, how many patients with endometrial cancer do you see in a typical month?

Presurvey

A 46-year-old woman with advanced endometrial cancer and a history of whole-pelvic radiation therapy presents for a routine visit 8 weeks after starting dostarlimab monotherapy. She reports that she has been experiencing cramping, stomach pain, and 5 episodes per day over baseline of watery, nonbloody diarrhea. A colonoscopy suggests immune processes, and her infectious workup is negative.

Along with supportive care, which of the following is the optimal next step for management of this patient’s diarrhea?